Yap TA - Search Results

1

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS. Carden CP, et al. Among authors: yap ta. Drug Discov Today. 2010 Feb;15(3-4):88-97. doi: 10.1016/j.drudis.2009.11.006. Epub 2009 Dec 2. Drug Discov Today. 2010. PMID: 19961955 Review.

2

Envisioning the future of early anticancer drug development.

Yap TA, Sandhu SK, Workman P, de Bono JS. Yap TA, et al. Nat Rev Cancer. 2010 Jul;10(7):514-23. doi: 10.1038/nrc2870. Epub 2010 Jun 10. Nat Rev Cancer. 2010. PMID: 20535131 Review.

3

Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

Yap TA, Workman P. Yap TA, et al. Annu Rev Pharmacol Toxicol. 2012;52:549-73. doi: 10.1146/annurev-pharmtox-010611-134532. Annu Rev Pharmacol Toxicol. 2012. PMID: 22235862 Review.

4

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development.

Yap TA, Banerji U, de Bono JS, Workman P. Yap TA, et al. J Clin Oncol. 2016 Jul 10;34(20):2431-2. doi: 10.1200/JCO.2016.67.0075. Epub 2016 May 2. J Clin Oncol. 2016. PMID: 27138581 No abstract available.

5

Drug discovery in advanced prostate cancer: translating biology into therapy.

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Yap TA, et al. Nat Rev Drug Discov. 2016 Oct;15(10):699-718. doi: 10.1038/nrd.2016.120. Epub 2016 Jul 22. Nat Rev Drug Discov. 2016. PMID: 27444228 Review.

6

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA. O'Carrigan B, et al. Among authors: yap ta. Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318518 Free PMC article.

7

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.

Collins DC, Sundar R, Constantinidou A, Dolling D, Yap TA, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Collins DC, et al. Among authors: yap ta. BMC Cancer. 2020 Dec 9;20(1):1210. doi: 10.1186/s12885-020-07662-y. BMC Cancer. 2020. PMID: 33298007 Free PMC article.

8

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Curr Opin Pharmacol. 2008. PMID: 18619560 Review.

9

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.

10

Reovirus therapy in cancer: has the orphan virus found a home?

Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS. Yap TA, et al. Expert Opin Investig Drugs. 2008 Dec;17(12):1925-35. doi: 10.1517/13543780802533401. Expert Opin Investig Drugs. 2008. PMID: 19012507 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters